Celltrion launches three new biosimilars in Brazil

By Maekyung News Service

Celltrion Inc. has launched three additional biosimilars in Brazil, expanding its local product portfolio to 10, the company said Thursday.

The new products are Qoyvolma, a treatment for autoimmune diseases containing ustekinumab and marketed as Steqeyma in other markets, and Stoboclo and Osenvelt, denosumab-based treatments for bone diseases.

Celltrion plans to offer the products in various dosages and formulations to better meet the needs of local healthcare providers and patients, while expanding prescriptions and sales.

Its Brazilian subsidiary will leverage its sales infrastructure and local network to establish the new products in the market. The company also expects its reliable supply capabilities, competitive pricing, and product quality to support its expansion in Brazil.

Celltrion plans to launch two more products by year-end: Eydenzelt, an aflibercept treatment for eye diseases, and Aptozma, a tocilizumab treatment for autoimmune diseases.

“We will continue to expand our product portfolio and therapeutic areas, accelerating growth in Brazil and other Latin American markets,” said a company official.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.